Bio-Rad Laboratories logo

Bio-Rad LaboratoriesNYSE: BIO

Profile

Sector:

Healthcare

Country:

United States

IPO:

27 February 1980

Next earnings report:

14 February 2025

Last dividends:

N/A

Next dividends:

N/A
$9.06 B
-61%vs. 3y high
92%vs. sector
-vs. 3y high
-vs. sector
-35%vs. 3y high
43%vs. sector
-55%vs. 3y high
53%vs. sector

Price

after hours | Wed, 20 Nov 2024 22:19:58 GMT
$323.69+$3.19(+1.00%)

Dividend

No data over the past 3 years
$649.73 M$682.15 M
$649.73 M$653.17 M

Analysts recommendations

Institutional Ownership

BIO Latest News

BIO-key Reports Q3'24 Revenue Rose 18% to $2.1M, Reduced Q3'24 Net Loss, and Improved Cash Position; Hosts Investor Call Tomorrow, Fri. Nov. 15th, 10am ET
globenewswire.com14 November 2024 Sentiment: POSITIVE

BIO-key (BKYI) Reports Q3'24 Revenue Rose 18% to $2.1M, Reduced Q3'24 Net Loss, Improved Cash Position; Hosts Conf. Call Tomorrow, Fri. Nov. 15th, 10am ET.

UPDATED: BIO-TECHNE ANNOUNCES IVDR CERTIFIED HEMATOLOGY CONTROLS AND CALIBRATORS
prnewswire.com11 November 2024 Sentiment: POSITIVE

R&D Systems Hematology Controls and Calibrators has completed the Class B Certification under the new European Union In Vitro Diagnostic Regulation This press release updates the IVDR Classification to Class B from the prior Class C.  MINNEAPOLIS , Nov. 11, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) has recently achieved In Vitro Diagnostic Regulation (IVDR) certification for its R&D Systems Hematology Controls and Calibrators.

BIO-TECHNE ANNOUNCES IVDR CERTIFIED HEMATOLOGY CONTROLS AND CALIBRATORS
prnewswire.com11 November 2024 Sentiment: POSITIVE

R&D Systems Hematology Controls and Calibrators has completed the Class C Certification under the new European Union In Vitro Diagnostic Regulation MINNEAPOLIS , Nov. 11, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) has recently achieved In Vitro Diagnostic Regulation (IVDR) certification for its R&D Systems Hematology Controls and Calibrators. This certification confirms that the products comply with the regulations and guidelines set forth by the European Union for in-vitro diagnostic devices.

BIO-TECHNE TO PRESENT AT INVESTOR CONFERENCES
prnewswire.com08 November 2024 Sentiment: POSITIVE

MINNEAPOLIS , Nov. 8, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor conferences: UBS Global Healthcare Conference November 12, 2024 9:30 AM PST Stifel 2024 Healthcare Conference November 19, 2024 8:00 AM EST Stephens NASH 2024 Conference November 20, 2024 11:00 AM CST A live webcast of the presentations can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar. About Bio-Techne Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities.

Interpreting Bio-Rad (BIO) International Revenue Trends
zacks.com04 November 2024 Sentiment: POSITIVE

Examine the evolution of Bio-Rad's (BIO) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.

Tiziana Life Sciences to showcase breakthrough therapies at BIO-Europe 2024 Conference
proactiveinvestors.com01 November 2024 Sentiment: POSITIVE

Tiziana Life Sciences Ltd (NASDAQ:TLSA) said it will participate in the upcoming BIO-Europe 2024 conference in Stockholm. The event will allow Tiziana to engage with industry leaders, potential collaborators, and investors, emphasizing its recent clinical advancements, particularly data from its combination study involving Ozempic, a GLP-1 agonist.

Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study Data
globenewswire.com01 November 2024 Sentiment: POSITIVE

NEW YORK, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced its participation in the BIO-Europe 2024 conference, taking place November 4-6 in Stockholm, Sweden. As part of the conference's partnering meetings, Tiziana will engage with industry leaders, potential collaborators, and investors to discuss recent clinical progress, including data from its combination study involving Ozempic, a GLP-1 agonist.

BIO Q3 Earnings and Revenues Surpass Estimates, Stock Up Aftermarket
zacks.com31 October 2024 Sentiment: POSITIVE

Bio-Rad witnesses growth across the Clinical Diagnostics segment in the third quarter, primarily driven by an increased demand for quality control and immunology products.

Bio-Rad Laboratories, Inc. (BIO) Q3 2024 Earnings Call Transcript
seekingalpha.com30 October 2024 Sentiment: POSITIVE

Bio-Rad Laboratories, Inc. (NYSE:BIO ) Q3 2024 Earnings Conference Call October 30, 2024 5:00 PM ET Company Participants Edward Chung - Vice President of Investor Relations Norman Schwartz - Chairman of the Board, President & Chief Executive Officer Jon DiVincenzo - President & Chief Operating Officer Roop Lakkaraju - Executive Vice President & Chief Financial Officer Conference Call Participants Patrick Donnelly - Citi Dan Leonard - UBS Brandon Couillard - Wells Fargo Jack Meehan - Nephron Research Tycho Peterson - Jefferies Operator Hello, everyone, and welcome to today's Bio-Rad Third Quarter 2024 Results Conference Call and Webcast. At this time to get started, all participants are in a listen-only mode.

BIO-TECHNE DECLARES DIVIDEND
prnewswire.com30 October 2024 Sentiment: POSITIVE

MINNEAPOLIS , Oct. 30, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended September 30, 2024. The quarterly dividend will be  payable November 22, 2024, to all common shareholders of record on November 11, 2024.

What type of business is Bio-Rad Laboratories?

Bio-Rad Laboratories, Inc. produces and supplies products for scientific research, healthcare, analytical chemistry, and other markets with products and systems used for separating complex chemical and biological materials and identifying, analyzing, and purifying their components. Bio-Rad operates in six industry segments: scientific research, clinical diagnostics, food industry, spectroscopy, and bioengineering. The segments operate worldwide. Bio-Rad's clients include hospitals, major research institutions, biotechnology and pharmaceutical companies, as well as secondary and tertiary academic institutions. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

What sector is Bio-Rad Laboratories in?

Bio-Rad Laboratories is in the Healthcare sector

What industry is Bio-Rad Laboratories in?

Bio-Rad Laboratories is in the Medical Devices industry

What country is Bio-Rad Laboratories from?

Bio-Rad Laboratories is headquartered in United States

When did Bio-Rad Laboratories go public?

Bio-Rad Laboratories initial public offering (IPO) was on 27 February 1980

What is Bio-Rad Laboratories website?

https://www.bio-rad.com

Is Bio-Rad Laboratories in the S&P 500?

No, Bio-Rad Laboratories is not included in the S&P 500 index

Is Bio-Rad Laboratories in the NASDAQ 100?

No, Bio-Rad Laboratories is not included in the NASDAQ 100 index

Is Bio-Rad Laboratories in the Dow Jones?

No, Bio-Rad Laboratories is not included in the Dow Jones index

When was Bio-Rad Laboratories the previous earnings report?

No data

When does Bio-Rad Laboratories earnings report?

The next expected earnings date for Bio-Rad Laboratories is 14 February 2025